Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review)

Vascular aging, early vascular aging or supernormal vascular aging are concepts used for estimating the cardiovascular risk at a certain age. From the famous line of Thomas Sydenham that "a man is as old as his arteries" to the present day, clinical studies in the field of molecular biolog...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2022-05, Vol.12 (6), p.803
Main Authors: Adam, Cristina Andreea, Anghel, Razvan, Marcu, Dragos Traian Marius, Mitu, Ovidiu, Roca, Mihai, Mitu, Florin
Format: Article
Language:English
Subjects:
Aging
arterial stiffness
Arteries
Atherosclerosis
Biomarkers
Blood pressure
Calcification
Cardiovascular diseases
cardiovascular risks
Cell activation
Collagen
Diabetes
Diabetes mellitus
Disease
early vascular aging
Endothelial cells
Endothelium
Extracellular matrix
Fibroblasts
Glucose
Health risks
Heart failure
Homeostasis
Hypertension
Hypoxia
Inhibitors
Low density lipoprotein
Molecular biology
Morbidity
Mortality
Oxidative stress
Review
Risk analysis
Risk factors
SGLT2 inhibitors
Sodium
Stiffness
vascular aging
Vasodilation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vascular aging, early vascular aging or supernormal vascular aging are concepts used for estimating the cardiovascular risk at a certain age. From the famous line of Thomas Sydenham that "a man is as old as his arteries" to the present day, clinical studies in the field of molecular biology of the vasculature have demonstrated the active role of vascular endothelium in the onset of cardiovascular diseases. Arterial stiffness is an important cardiovascular risk factor associated with the occurrence of cardiovascular events and a high risk of morbidity and mortality, especially in the presence of diabetes. Sodium-glucose cotransporter 2 inhibitors decrease arterial stiffness and vascular resistance by decreasing endothelial cell activation, stimulating direct vasorelaxation and ameliorating endothelial dysfunction or expression of pro-atherogenic cells and molecules.
ISSN:2075-1729
2075-1729
DOI:10.3390/life12060803